Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-17

Study Completion Date

2020-10-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A better understanding of the HD pathogenesis mechanisms may lead to a better understanding of disease pathology, progression and development of targeted therapies.

\[11C\]CHDI-00485180-R and \[11C\]CHDI-00485626 are two novel mutant huntingtin aggregate binding PET radioligands which have already demonstrated sensitivity to mutant huntingtin load in animal models. In the current study, the biodistribution and dosimetry of both these ligands will be investigated in young healthy volunteers according to a standard approach, in 3 subjects (including both genders) per tracer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.

NCT05360082

Huntington Disease

RECRUITING NA

Synaptic Density and Progression of Huntington's Disease.

NCT04701580

Huntington Disease

COMPLETED NA

Longitudinal SV2A and MRI in Premanifest HD

NCT06626412

Huntington Disease

RECRUITING NA

Imaging of Brain Receptors Using (11C)mGlu1

NCT01420952

Dosimetry Pharmacokinetics

TERMINATED PHASE1

Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease

NCT04012411

Huntington Disease

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For both groups, the dynamic whole-body distribution of the respective tracer labelled with \[11C\] will be measured after IV administration of 370 MBq. Two venous catheters, one on each arm, will be used for : 1/ the injection of \[11C\]CHDI-00485180-R or \[11C\]CHDI-00485626 tracer solution and 2/ for venous blood sampling (blood biochemistry and metabolites).

All images will be acquired using the SIEMENS Truepoint Biograph 40 PET-CT scanner. First, a CT scout will be acquired to set the axial field of view (FOV). The axial FOV should extend from the top of the head to the middle of the thighs (approximately 6-7 bed positions). Then, a low dose CT will be acquired for enabling PET attenuation correction and anatomical information (organ delineation). Following the CT, 10 sets of WB 3D PET images in total will be acquired sequentially. The first set of 9 whole body PET scans (scan segment 1) will be acquired, starting at the time of injecting \[11C\]CHDI-00485180-R solution or \[11C\]CHDI-00485626 solution. After this sequence of PET acquisitions, which will take up to 100 min, the subject will be moved out of the scanner and will be encouraged to void the bladder. After a 30 minute break, the subject will be repositioned in the PET/CT scanner and a second low dose CT will be acquired. WB scan 10 (scan segment 2) will be started at 2 hours after \[11C\]CHDI-00485180-R or \[11C\]CHDI-00485626 injection, scanning for a total scan duration of about 28 minutes.

During the first WB PET/CT scan segment, 6 venous blood samples (4 mL each) per subject will be taken at 5, 10, 20, 40, 60 and 100 min after \[11C\]CHDI-00485180-R or \[11C\]CHDI-00485626 injection. This will allow testing and further optimization of the HPLC metabolite analysis for future brain imaging studies with full kinetic modelling and quantification.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Huntington Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

[11C]CHDI-180R

Biodistribution and whole-body dosimetry for \[11C\]CHDI-00485180-R in 3 healthy volunteers.

[11C]CHDI-00485180-R

Intervention Type OTHER

Mutant huntingtin aggregate binding PET radioligand.

[11C]CHDI-626

Biodistribution and whole-body dosimetry for \[11C\]CHDI-00485626 in 3 healthy volunteers.

[11C]CHDI-00485626

Intervention Type OTHER

Mutant huntingtin aggregate binding PET radioligand.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[11C]CHDI-00485180-R

Mutant huntingtin aggregate binding PET radioligand.

Intervention Type OTHER

[11C]CHDI-00485626

Mutant huntingtin aggregate binding PET radioligand.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female subjects, age between 18 and 55 years old
* Subject is judged to be in good health by the investigator on the basis of medical history. When still in doubt, a full physical and neurological examination can be conducted

Exclusion Criteria

* Subject has a history of major internal disease that may interfere with the investigations (especially liver and kidney disease, cancer or uncontrolled diabetes).
* Subject has any history of a major neurological or psychiatric disorder
* Subject is currently smoker (\> 20 cigarettes or equivalent/day) a user (including ''recreational use'') of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse.
* Subject has had exposure to ionizing radiation (\> 1 mSv) in other research studies within the last 12 months.
* Subject suffers from claustrophobia or cannot tolerate confinement during PET-CT scanning procedures; subject cannot lie still for 90 minutes inside the scanner.
* Subject is unwilling to avoid unusual, unaccustomed, or strenuous physical activity (i.e. weight lifting, running, bicycling) 3 days before and during the day of scanning.
* Subject does not understand the study procedure
* Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator.
* Subject is potentially pregnant (hCG will be performed in women with childbearing potential).
* Allergy for local anesthesia (lidocaine)

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes